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Introduction
Angiogenesis is the process of new blood vessel for-
mation. It is an important process in the growth of
malignant tumors as tumors need to establish their
own blood supply to grow beyond 1–2 mm in diame-
ter. The predominant regulator of tumor angiogenesis
is vascular endothelial growth factor (VEGF),1,2 which
is the only angiogenic factor known to be present
throughout the entire tumor lifecycle.3 This continu-
ous expression, along with the proposed genetic sta-
bility of VEGF and endothelial cells,2,4 makes direct
and continuous targeting of VEGF an important anti-
tumor strategy.3
VEGF-Trap (aflibercept), an engineered protein
which contains the extracellular domain 2 of VEGF
receptor-1 (VEGFR-1, Flt-1) and extracellular domain
3 of VEGFR-2 (Flk-1, KDR) fused to the Fc portion
of human immunoglobulin G1 (Figure 1), binds to all
isoforms of VEGF and to placental growth factor.5
VEGF-Trap exerts its antiangiogenic effects through
regression of tumor vasculature,6,7 remodeling or nor-
malization of surviving vasculature,8,9 and inhibition
of new tumor vessel growth.9 Given the central role
of angiogenesis in tumor development, antiangiogenic
agents should be considered a pillar of anticancer ther-
apy, alongside surgery, radiotherapy, chemotherapy,
and hormonal therapy.
This review examines the effects of VEGF-Trap on
tumor vasculature, and how these translate into preclin-
ical and clinical efficacy. This review also examines the
preclinical and clinical benefits of incorporating VEGF-
Trap into anticancer treatment strategies, including
which agents can be combined with VEGF-Trap.
Effect of VEGF-Trap on Tumor
Vasculature
VEGF-Trap is a composite decoy receptor based on
VEGFR-1 and VEGFR-2 fused to an Fc segment of
immunoglobulin G1 that binds specifically to VEGF,
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preventing activation of the VEGF receptor. VEGF-
Trap inhibits VEGF extracellularly and may therefore
inhibit angiogenesis without disrupting targets outside
the VEGF pathway. Based on preclinical models, it has
been proposed that VEGF-Trap exerts antivascular
effects by rapid regression of existing tumor vessels, as
shown by significant reductions in microvascular den-
sity,6,7 remodeling or normalization of surviving mature
vasculature,8,9 and ongoing inhibition of new tumor
vessel growth.9 This results in maintenance of a more
functional and normal vasculature, potentially improved
capacity for drug delivery, and inhibition of tumor
growth and metastasis.
Preclinical models have indicated that VEGF-Trap
can cause regression of existing tumor vasculature. Sig-
nificant reductions in tumor vascular volume and den-
sity following a single infusion of VEGF-Trap alone
have been reported. In a preclinical model using human
neuroblastoma xenografts, high doses of VEGF-Trap
can lead to regression of co-opted vascular structures.6
Huang et al10 reported that VEGF-Trap abolishes ma-
ture, preexisting vasculature in established xenografts.
Fukasawa and Korc11 found that VEGF-Trap, initi-
ated 2 days after tumor cell inoculation, markedly de-
creases tumor microvessel density in the subcutaneous
growth of 4 pancreatic cancer cell lines. Kadenhe-
Chiweshe et al12 found that treatment with VEGF-Trap
in late-stage hepatoblastoma xenografts results in the
initial collapse of the vasculature. Frischer et al13 re-
ported that VEGF-Trap induces regression of the vessels
of established Wilms’ tumor xenografts. Treatment
with VEGF-Trap nearly eradicates tumor vasculature.
Rare persisting vessels are characterized by a large cal-
iber, quiescence (lacking proliferation/apoptosis), and
arterialization (both phenotypic and molecular), result-
ing in nearly avascular tumors. Persistent vessels in
tumors treated with VEGF-Trap display specific mor-
phologic and molecular features, suggestive of arteri-
alization.13 Huang et al14 confirmed this finding.
Similar to Avastin, which results in the inhibition
of new vessel growth in preclinical models,15,16 VEGF-
Trap has a marked effect on preexisting or newly
formed vessels,9,17 which are required for tumor growth
and metastasis.18 In preclinical models, VEGF-Trap has
been shown to remodel or normalize the surviving
mature vasculature of tumors.8,9
Inai et al9 reported that treatment with VEGF-
Trap causes robust and early changes in endothelial
cells, pericytes, and the basement membrane of vessels
in spontaneous islet-cell tumors of RIP-Tag2 transgenic
mice and in subcutaneously implanted Lewis lung car-
cinomas. They found that within 24 hours, endothelial
fenestrations in RIP-Tag2 tumors disappeared, vascular
sprouting was suppressed, and patency and blood flow
ceased in some vessels. By 7 days, vascular density de-
creased more than 70%. In both tumors, pericytes did
not degenerate to the same extent as endothelial cells,
and those on surviving tumor vessels acquired a more
normal phenotype.9 Byrne et al8 found that systemic
administration of VEGF-Trap results in dramatic
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Figure 1. (A) Structure of vascular endothelial growth factor (VEGF) recep-
tors and VEGF-Trap. VEGF receptor-1 (VEGFR-1) and VEGFR-2 both contain
7 extracellular domains, which differ between the 2 receptors. The solu-
ble VEGF-Trap was created by fusion of domain 2 of VEGFR-1 and domain
3 of VEGFR-2 with the Fc portion of immunoglobulin G1.5 (B) The VEGF
pathway. (C) Direct inhibition of VEGF with VEGF-Trap blocks the angio-
genic cascade.
remodeling of the blood vessels in disseminated ovar-
ian carcinoma. Baffert et al17 identified the sequence
of events and the fate of endothelial cells, pericytes,
and the vascular basement membrane during capillary
regression in mouse tracheas after VEGF signaling was
blocked with VEGF-Trap. Within 1 day, patency was
lost and fibrin accumulated in some tracheal capillar-
ies. Apoptotic endothelial cells marked by activated
caspase-3 were present in capillaries without blood
flow. VEGF inhibition was accompanied by a 19%
decrease in tracheal capillaries over 7 days and 30%
over 21 days. During this period, pericytes moved away
from regressing capillaries onto surviving vessels. Empty
sleeves of basement membrane were left behind by
regressing endothelial cells, persisted for approximately
2 weeks, and served as a scaffold for vascular regrowth
after treatment ended. The amount of regrowth was
limited by the number of surviving basement mem-
brane sleeves. Baffert et al’s17 findings demonstrate
that after treatment with VEGF-Trap, some normal
capillaries regress in a systematic sequence of events
initiated by a cessation of blood flow, followed by apop-
tosis of endothelial cells, migration of pericytes away
from regressing vessels, and formation of empty base-
ment membrane sleeves that can facilitate capillary
regrowth.
These effects of VEGF-Trap on tumor vascular
may help make tumor cells more sensitive to cytotoxic
chemotherapy.19–21 In terms of clinical significance,
normalization of tumor vasculature by VEGF-Trap
can maximize efficacy of concomitant therapy. The un-
regulated nature of tumor angiogenesis leads to the
production of structurally and functionally abnormal
vasculature, characterized by a number of different
features as follows: increased vessel density, diameter,
length and tortuosity, abnormally high interstitial fluid
pressure, and increased vascular permeability. These
abnormalities prevent the effective delivery of therapy to
the tumor. The entry of large molecules, such as
chemotherapeutic agents, into the tumor is impeded.
Hypoxia results from inconsistent oxygen supply within
the tumor, producing regions that are resistant to radio-
therapy and some cytotoxic agents.19,20 Antiangiogenic
therapy, such as VEGF-Trap, normalizes the tumor vas-
culature, pruning excess vessels and reducing intersti-
tial fluid pressure and vessel permeability. This increases
both the delivery of anticancer agents to the tumor
and the sensitivity of tumor cells to those agents.
Effect of VEGF-Trap on Solid Tumors
Solid tumors are unable to grow beyond a size of
1–2 mm, or undergo further growth and metastasis,
without the ability to establish their own blood sup-
ply through angiogenesis.2,4,22 An anticancer agent such
as VEGF-Trap, which inhibits this process, should
therefore have activity against all types of solid tumors.
Preclinical studies of VEGF-Trap in different tumor
types have demonstrated that VEGF inhibition pro-
duces preclinical benefits for the xenograft models
(Table 1).6–8,10–12,23–26
Holash et al7 found that VEGF-Trap effectively
suppresses tumor growth and vascularization in vivo,
resulting in stunted and almost completely avascular
tumors. In a preclinical model using human neuro-
blastoma xenografts, high-dose VEGF-Trap causes the
greatest inhibition of tumor growth (81% compared
with controls).6 Huang et al10 reported that VEGF-
Trap causes marked tumor regression, including
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Table 1. Preclinical studies of VEGF-Trap (aflibercept) in different tumor type xenograft models
Tumor types VEGF-Trap schedules
Tumor growth 
Ref.
inhibition rate (%)
NGP-GFP neuroblastoma 500 μg, i.p. twice weekly for 5.5 wk 81 6
C6 glioma; A673 rhabdomyosarcoma; 2.5 mg/kg or 25 mg/kg, s.c. twice weekly for 2 wk 85–95 7
B16F10.9 melanoma (C6 & B16F10.9) or 3.0 wk (A673)
SKOV-3 & OVCAR-3 ovarian cancers 25 mg/kg, s.c. twice weekly for 5 wk 56 8
SK-NEP-1 human Wilms’ tumor 500 μg, i.p. twice weekly for 36 d 79.3 10
BxPC3, PANC-1, T3M4 & COLO-357 25 mg/kg, s.c. twice weekly for 6 wk 92–97 11
pancreatic cancers
HUH-6 hepatoblastoma 500 μg, i.p. twice weekly for 44 d 54 12
ESFT cell lines: RD-ES & A673 2.5 mg/kg or 25 mg/kg, s.c. twice weekly for 4 wk 60–75 23
RENCA renal cell carcinoma 10 mg/kg or 25 mg/kg, i.p. twice weekly for 22 d 87 ± 14 24
U87 glioblastoma 25 mg/kg, s.c. twice weekly over 3 wk NS 25
BT474 breast cancer 2.5, 10, or 25 mg/kg, i.p. twice weekly for 47 d 80–90 26
VEGF = vascular endothelial growth factor; i.p. = intraperitoneal injection; s.c. = subcutaneously; ESFT = Ewing’s sarcoma family of tumors; RENCA = murine 
syngeneic renal cell carcinoma cells; NS = not stated.
regression of lung micrometastases. Byrne et al8 found
that systemic administration of VEGF-Trap inhibits the
growth of disseminated cancer. Fukasawa and Korc11
found that VEGF-Trap, initiated 2 days after tumor
cell inoculation, suppresses the subcutaneous growth
of 4 pancreatic cancer cell lines and also attenuates
intrapancreatic tumor growth and metastasis in an or-
thotopic model using PANC-1 cells when initiated 
3 weeks after tumor implantation. Therefore, VEGF-
Trap may represent an exceedingly useful therapeutic
modality for pancreatic ductal adenocarcinoma. Frischer
et al13 reported that VEGF-Trap induces regression
of established Wilms’ tumor xenografts and reduces
the size but not the incidence of pre-existing metas-
tases. After biweekly treatment with VEGF-Trap,
tumors are significant smaller. The incidence of lung
metastasis is also decreased.13 Dalal et al23 reported
that VEGF-Trap delays subcutaneous growth in the 
6 Ewing’s sarcoma family of tumor cell line xenograft
models. Kadenhe-Chiweshe et al12 found that treat-
ment with VEGF-Trap in late-stage hepatoblastoma
xenografts results in significant tumor regression.
Verheul et al24 tested the activity of VEGF-Trap in an
orthotopic murine model of renal cancer with sponta-
neous lung metastases. In the prevention model, VEGF-
Trap inhibited tumor growth by 87 ± 14% compared
with controls (p = 0.007) and significantly prolonged
survival. In the intervention model, VEGF-Trap inhib-
ited tumor growth by 74 ± 9% (p < 0.001), and the
formation of lung metastases was inhibited by 98%
(p < 0.004). The investigators concluded that VEGF-
Trap is a potent inhibitor of renal cell carcinoma growth
and metastasis formation. These results support fur-
ther clinical development of VEGF-Trap for renal cell
cancer and other cancer types.24 Gomez-Manzano et al25
tested VEGF-Trap in an intracranial glioma model.
They found that VEGF-Trap treatment was efficacious
in both initial and advanced phases of tumor develop-
ment by significantly increasing overall survival. Fur-
thermore, this effect was enhanced in animals treated
with more prolonged regimens. These results suggest
that VEGF-Trap could be effective in treating both
patients with recurrent or progressive resectable glio-
blastoma and patients who have undergone extensive
initial surgery, and indicate that the clinical success of
VEGF-Trap may depend on a prolonged treatment in
combined therapy aiming to simultaneously inhibit
angiogenesis and tumor invasion.25 Le et al26 found
that VEGF-Trap as a single treatment inhibited tumor
microvessel density, tumor vasculature, cell prolifera-
tion, and tumor growth of BT474 xenografts in a dose-
dependent manner from 2.5mg/kg to 25mg/kg. They
also found that VEGF-Trap decreased levels of both
human VEGF and placental growth factor protein 
in vivo.26 Lu et al27 reported that treatment with
VEGF-Trap caused 40–50% reductions in the growth
of A549 non-small cell lung cancer and PANC-1 pan-
creatic cancer xenografts and reduced microvessel
density in the tumors.
Preclinical and Clinical Benefits of
Incorporating VEGF-Trap into
Anticancer Treatment Strategies
The precise nature of VEGF inhibition by VEGF-Trap
makes this agent an ideal partner for combination with
approaches aimed at other mechanisms of tumor pro-
liferation. Additional benefit may be gained through
normalization of tumor vasculature by VEGF-Trap,
which reduces interstitial pressure and increases the
delivery of other agents to the tumor. The ability to
apply direct and continuous VEGF inhibition with
VEGF-Trap in combination with other treatment mo-
dalities may increase the available therapeutic options
in a number of tumor types. The specific chemotherapy,
radiotherapy, and targeted therapy agents used in clin-
ical practice vary considerably between tumor types.
Preclinical and clinical studies have investigated VEGF-
Trap in combination with the most frequently used
regimens in each indication (Table 2).26,28–46
Hu et al28 examined combination treatment with
VEGF-Trap and conventional cytotoxic chemother-
apy. Their study assessed the efficacy of VEGF-Trap
combined with paclitaxel in a mouse model of human
ovarian cancer, and they showed that tumor burden
after VEGF-Trap plus paclitaxel was reduced by approx-
imately 98% versus controls. Diaphragmatic and hepatic
tumors were not found in the VEGF-Trap plus pacli-
taxel group in contrast to controls, indicating a lack
of metastasis. The investigators concluded that com-
bination therapy with VEGF-Trap plus paclitaxel may
provide a novel, long-lasting therapeutic strategy for
treatment of patients with ovarian cancer.28 Le et al26
found that dual targeting of VEGF (with VEGF-
Trap) and human epidermal growth factor receptor-2
(HER2) (with trastuzumab) pathways results in greater
growth inhibition of HER2-overexpressing breast can-
cer xenografts than either agent alone. They found
that treatment with a combination of VEGF-Trap (2.5–
10 mg/kg) and trastuzumab (1 mg/kg) produced a
significantly greater inhibition of BT474 tumor growth
than that of either individual agent, and was associ-
ated with a greater inhibition of tumor microvessel den-
sity and tumor cell proliferation. Thus, VEGF-Trap 
in combination with trastuzumab produces superior
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growth inhibition of tumor xenografts that overex-
press HER2, which may result from inhibition of both
tumor angiogenesis and proliferation. This finding
indicates that similar mechanisms may contribute to
the clinical antitumor activity of trastuzumab in com-
bination with inhibitors of the VEGF signaling path-
way in women with breast cancer that overexpress
HER2.26 Lu et al27 reported that the combination of
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Table 2. Preclinical and clinical studies of VEGF-Trap (aflibercept) alone and in combination with anticancer treatment strategies
Preclinical studies
Tumor types Therapy schedules Main conclusions Ref.
BT474 breast cancer (1) VEGF-Trap (2.5 mg/kg) alone, twice weekly for 3 wk; VEGF-Trap + trastuzumab has 26
(2) VEGF-Trap (2.5 mg/kg) + trastuzumab (1 mg/kg), greater inhibition effect than 
twice weekly for 3 wk either alone, especially in 
tumors overexpressing HER2
OVCAR-3 ovarian cancer (1) VEGF-Trap (10 mg/kg) alone, thrice weekly for 4 wk; VEGF-Trap + paclitaxel is a novel 28
(2) VEGF-Trap (10 mg/kg) + paclitaxel (10 mg/kg), thrice strategy for treatment of 
weekly for 4 wk ovarian cancer
U87 glioblastoma (1) VEGF-Trap (2.5–25 mg/kg) alone, every 3 d for 3 wk; VEGF-Trap + radiation is a better 29
(2) VEGF-Trap (2.5–25 mg/kg), every 3 d for 3 wk + a strategy than radiation alone 
single dose of 10 Gy or fractionated RT (3 × 5 Gy) for treatment of glioblastoma
in 3 scheduling protocols
Phase I trials
Patients enrolled Therapy schedules Main conclusions Ref.
47 VEGF-Trap (0.3–7.0 mg/kg) alone i.v. every 2 wk Well tolerated 30
6 VEGF-Trap (2.0 mg/kg, 4.0 mg/kg) + FOLFOX-4 i.v. every 2 wk Safe 31
32 VEGF-Trap (2.0 mg/kg, 4.0 mg/kg, & 5.0 mg/kg) + FOLFOX-4 Safe 32
i.v. every 2 wk
10 VEGF-Trap (2.0 mg/kg, 4.0 mg/kg) + I-LV5FU2 i.v. every 2 wk Safe 33
27 VEGF-Trap (4.0 mg/kg) + I-LV5FU2 (standard dose) i.v. Safe 34
every 2 wk
38 VEGF-Trap (2.0–6.0 mg/kg) + I-LV5FU2 (fixed standard dose) Safe 35
i.v. every 2 wk
54 VEGF-Trap (2.0–9.0 mg/kg) + docetaxel (fixed dose 75 mg/m2)  Safe 36
i.v. every 3 wk
16 VEGF-Trap (4.0, 5.0, 6.0 mg/kg) + docetaxel (fixed dose Safe 37
75 mg/m2) & cisplatin (fixed dose 75 mg/m2) i.v. every 3 wk
32 VEGF-Trap (4.0, 6.0 mg/kg) i.v. every 2 wk followed by Safe 38
standard weekly i.v. gemcitabine (7 wk on/1 wk off, then 
3 wk on/1 wk off every 4 wk)
Phase II trials
Patients enrolled VEGF-Trap schedules Main conclusions Ref.
162 2 or 4 mg/kg, i.v. every 2 wk With antitumor effect on 39
EOC population
12 4 mg/kg, i.v. every 2 wk With activity in prolonging time 40
to repeat paracentesis
51 4 mg/kg, i.v. every 2 wk Well tolerated 41
94 4 mg/kg, i.v. every 2 wk Well tolerated 42
38 4 mg/kg, i.v. every 2 wk Well tolerated 43
22 4 mg/kg, i.v. every 2 wk Well tolerated 44
27 4 mg/kg, i.v. every 2 wk Safe 45
48 4 mg/kg, i.v. every 2 wk Well tolerated 46
VEGF = vascular endothelial growth factor; HER2 = human epidermal growth factor receptor-2; RT = radiation treatment; i.v. = intravenously; FOLFOX-4 = oxaliplatin/
5-fluorouracil/leucovorin; I-LV5FU2 = irinotecan, 5-fluorouracil and leucovorin; EOC = epithelial ovarian cancer.
6-(2-aminoethyl)amino-5-chlorouracil, a potent and
specific small-molecule inhibitor of the catalytic activity
of thymidine phosphorylase, and VEGF-Trap pro-
duced additive antitumor activity that was significantly
greater than VEGF-Trap alone in A549 non-small cell
lung cancer and PANC-1 pancreatic cancer xenografts.
These studies suggest that inhibitors of thymidine
phosphorylase could be used to augment the clinical
efficacy of VEGF-Trap.27 Wachsberger et al29 reported
that VEGF-Trap plus radiation was clearly better than
radiation alone in a U87 subcutaneous xenograft 
model. Although high-dose VEGF-Trap (10 mg/kg or
25 mg/kg) significantly reduces tumor growth over
that of radiation treatment alone, there is no addi-
tional benefit to combining high-dose VEGF-Trap with
radiation treatment, and it is unclear whether such
high doses can be used clinically without incurring
normal tissue toxicities. Thus, information on lower
doses of VEGF-Trap and ionizing radiation is of clini-
cal relevance.29
The safety, pharmacokinetics, and pharmacody-
namics of VEGF-Trap administered intravenously (IV)
every 2 weeks were evaluated in a phase I clinical
trial.30 The study enrolled 47 patients with refractory
solid tumors or non-Hodgkin’s lymphoma with ade-
quate organ function at doses ranging from 0.3 to
7.0 mg/kg IV every 2 weeks. Dose-limiting toxicities
were rectal ulceration and proteinuria at the 7.0 mg/
kg dose. Other mechanism-specific toxicities included
hypertension. On the basis of these observations and
pharmacokinetics, the recommended phase II dose of
VEGF-Trap as a single agent is 4 mg/kg every 2 weeks.
It was concluded that IV VEGF-Trap is well tolerated
at the dose levels tested.30
In phase I trials, large safety studies have explored
the combination of VEGF-Trap with a variety of chemo-
therapy agents and regimens such as FOLFOX-4,31,32
I-LV5FU2,33–35 docetaxel,36 docetaxel and cisplatin,37
and gemcitabine in advanced solid tumors.38 Phase II
trials in several diseases are ongoing, including ovarian
cancer,39,40 metastatic colorectal cancer,41 platinum-
and erlotinib-resistant non-small cell lung adenocarci-
noma,42 recurrent or metastatic gynecologic soft-tissue
sarcomas,43 recurrent or metastatic transitional cell
carcinoma,44 recurrent inoperable stage III or stage
IV melanoma,45 and recurrent temozolomide-resistant
glioblastoma.46
In conclusion, angiogenesis is a hallmark of cancer
throughout the lifecycle of the tumor. The predomi-
nant proangiogenic factor at the centre of the angio-
genic pathway is VEGF. The continuous expression of
VEGF by the tumor makes it a rational target for cancer
therapy. Direct inhibition of VEGF by VEGF-Trap
allows for greater precision than other means of tar-
geting the VEGF pathway, thereby avoiding unwanted
inhibitory effects on non-VEGF-meditated functions.
The key role of angiogenesis in tumor growth and
development suggests that the angiogenesis inhibitor
VEGF-Trap is likely to have potential benefits in the
treatment of multiple tumor types. Numerous preclin-
ical studies have demonstrated the efficacy of VEGF-
Trap in ovarian cancer, breast cancer, non-small cell
lung cancer, pancreatic cancer, neuroblastoma, glioblas-
toma, glioma, hepatoblastoma, Ewing’s sarcoma family
of tumors, Wilms’ tumor, and renal cell cancer xeno-
graft models. In preclinical studies, VEGF-Trap has
proven its efficacy in combination with a broad range of
conventional anticancer therapies, including cytotoxic
chemotherapy, radiotherapy, and targeted therapy.
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